Collecting data on cellular immunotherapy for lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather clinical data from adult patients with relapsed or refractory non-Hodgkin's lymphoma who are receiving cellular immunotherapy. The study will collect efficacy and safety data over a period from January 2017 to December 2040, focusing on various types of cellular immunotherapy treatments. Investigators will analyze the data to determine optimal diagnostic and treatment plans based on clinical practice, without any intervention from the study itself. Data will be collected at multiple time points, including before treatment, on the day of infusion, and during follow-up visits within 24 months post-infusion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients with a confirmed diagnosis of r/r B-NHL (including r/r DLBCL, r/r FL, r/r MCL, HGBL-NOS, FL3b, r/r MZL, transformed lymphomas such as MCL) and r/r T-cell lymphoma, who have received informed consent waivers;
* Patients who have received or are receiving cellular immunotherapy, with cellular immunotherapy products including the following categories: cytokine-induced killer cell therapy (CIK), tumor-infiltrating lymphocytes (TIL), cytokine-induced killer cell-dendritic cell mixed therapy (DC-CIK), chimeric antigen receptor T cells, NK cells or macrophage therapy (CAR-T, CAR-NK, CAR-M), T-cell receptor chimeric T cell therapy (TCR-T), dendritic cell therapy.

Exclusion Criteria:

* NA

Where it's running

• Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Weili Zhao
• Email: zwl_trial@163.com
• Phone: +862164370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JMBI-001 in MYC-Positive Advanced Cancers

  This study tests JMBI-001 to see if it is safe and tolerable for adults with MYC-positive advanced cancers.

  Recruiting Phase 1/2 Chengdu Anticancer Bioscience, Ltd. · Beijing, Beijing Municipality · NCT07864701

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

  We’re testing whether GSK5926371 is safe and can show activity in adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatment.

  Recruiting at 22 sites Phase 1/2 GlaxoSmithKline · Iowa City, Iowa and 21 other locations · NCT07607925

• AI tool to spot and reduce missed doses of oral medicines for Non-Hodgkin lymphoma patients

  This project will try an AI-based system to detect early risks of not taking prescribed oral treatments and alert clinicians for adults with Non-Hodgkin lymphoma treated at Grand Hôpital de Charleroi.

  Recruiting Grand Hôpital de Charleroi · Charleroi, Hainaut · NCT07546188

• MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma

  This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.

  Recruiting at 54 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 53 other locations · NCT07519772

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.